Increasing cumulative cabergoline dose in patients with prolactinoma improves metabolic parameters independently of decrease in prolactin levels

Year 2025, Volume: 11 Issue: 1, 80 - 87, 04.01.2025

Ahmet Numan Demir , Alara Birol , Dilan Özaydın , Serdar Şahin , Pınar Kadıoğlu

https://doi.org/10.18621/eurj.1564695

Abstract

Objectives: In prolactinoma patients treated with cabergoline, all of whom achieved normoprolactinemia, longitudinal changes in metabolic parameters and the factors influencing these changes were investigated.

Methods: This retrospective-longitudinal study was conducted at a pituitary disease center. Medical records of newly diagnosed prolactinoma patients between 2013 and 2023 were reviewed. After applying exclusion criteria, 102 prolactinoma patients were included in the final analysis. Clinical and laboratory parameters of prolactinoma patients were recorded. Metabolic parameters assessed were fasting plasma glucose, lipid levels, fasting insulin levels, HbA1c levels, and Homeostatic Model Assessment-Insulin Resistance (HOMA-IR) levels. Subsequently, metabolic parameters assessed at the initial and final visits were compared, and factors influencing these parameters were analyzed.

Results: All prolactinoma patients were treated with cabergoline, and all were in remission at their final visit. The treatment significantly reduced fasting plasma glucose, HbA1c, and LDL cholesterol levels (P<0.05). Although there were improvements in other lipid parameters, fasting insulin, BMI, and HOMA-IR compared to baseline, the differences were not statistically significant. A correlation analysis was conducted to identify factors influencing fasting plasma glucose, HbA1c, and LDL cholesterol levels at the final visit in prolactinoma patients. The analysis revealed that only the cumulative dose of cabergoline significantly impacted all three metabolic parameters (P<0.05).

Conclusions: Cabergoline not only balances prolactin levels but also directly improves metabolic health. Current and future evidence clearly indicates that dopamine agonists like cabergoline could be an effective treatment not only for patients with prolactinomas but also for individuals affected by metabolic disorders without hyperprolactinemia.

Keywords

Cabergoline, prolactinoma, glucose profile, lipid profile, metabolism

Ethical Statement

The Ethics Committee of Istanbul University-Cerrahpasa approved the study (Approval Number: 16.10.2023-711105)

References

• 1. Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005;8(1):3-6. doi: 10.1007/s11102-005-5079-0.
• 2. Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med. 2003;349(21):2035-2041. doi: 10.1056/NEJMcp025334.
• 3. Pirchio R, Graziadio C, Colao A, Pivonello R, Auriemma RS. Metabolic effects of prolactin. Front Endocrinol (Lausanne). 2022;13:1015520. doi: 10.3389/fendo.2022.1015520.
• 4. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab. 2006;17(3):110-116. doi: 10.1016/j.tem.2006.02.005.
• 5. Auriemma RS, De Alcubierre D, Pirchio R, Pivonello R, Colao A. The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev Endocrinol Metab. 2018;13(2):99-106. doi: 10.1080/17446651.2018.1434412.
• 6. Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722-740. doi: 10.1038/s41574-023-00886-5.
• 7. Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol. 2003;2(1):23-32. doi: 10.2165/00024677-200302010-00003.
• 8. Abbasi F, Okeke Q, Reaven GM. Evaluation of fasting plasma insulin concentration as an estimate of insulin action in nondiabetic individuals: comparison with the homeostasis model assessment of insulin resistance (HOMA-IR). Acta Diabetol. 2014;51(2):193-197. doi: 10.1007/s00592-013-0461-2.
• 9. Morales J, Schneider D. Hypoglycemia. Am J Med. 2014;127(10 Suppl):S17-S24. doi: 10.1016/j.amjmed.2014.07.004.
• 10. Baptista T, Lacruz A, de Mendoza S, et al. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry. 2000;33(3):81-88. doi: 10.1055/s-2000-8451.
• 11. Doknic M, Pekic S, Zarkovic M, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002;147(1):77-84. doi: 10.1530/eje.0.1470077.
• 12. Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf). 1998;48(5):547-553. doi: 10.1046/j.1365-2265.1998.00403.x.
• 13. Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab. 2007;9(4):464-476. doi: 10.1111/j.1463-1326.2006.00671.x.
• 14. Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000;71(1):68-78. doi: 10.1159/000054522.
• 15. Macotela Y, Triebel J, Clapp C. Time for a New Perspective on Prolactin in Metabolism. Trends Endocrinol Metab. 2020;31(4):276-286. doi: 10.1016/j.tem.2020.01.004.
• 16. Sorenson RL, Brelje TC. Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res. 1997;29(6):301-307. doi: 10.1055/s-2007-979040.
• 17. Weinhaus AJ, Stout LE, Bhagroo NV, Brelje TC, Sorenson RL. Regulation of glucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy. J Endocrinol. 2007;193(3):367-381. doi: 10.1677/JOE-07-0043.
• 18. Landgraf R, Landraf-Leurs MM, Weissmann A, Hörl R, von Werder K, Scriba PC. Prolactin: a diabetogenic hormone. Diabetologia. 1977;13(2):99-104. doi: 10.1007/BF00745135.
• 19. Johnston DG, Alberti KG, Nattrass M, et al. Hyperinsulinaemia in hyperprolactinaemic women. Clin Endocrinol (Oxf). 1980;13(4):361-368. doi: 10.1111/j.1365-2265.1980.tb03397.x.
• 20. Schernthaner G, Prager R, Punzengruber C, Luger A. Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia. 1985;28(3):138-142. doi: 10.1007/BF00273860.
• 21. Atmaca A, Bilgici B, Ecemis GC, Tuncel OK. Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia. Endocrine. 2013;44(3):756-761. doi: 10.1007/s12020-013-9931-0.
• 22. Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet. 2001;357(9253):354-357. doi: 10.1016/s0140-6736(00)03643-6.
• 23. Kok P, Roelfsema F, Frölich M, Meinders AE, Pijl H. Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab. 2004;89(9):4445-4449. doi: 10.1210/jc.2003-032184.
• 24. Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23(8):1154-1161. doi: 10.2337/diacare.23.8.1154.
• 25. Holt RI, Barnett AH, Bailey CJ. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab. 2010;12(12):1048-1057. doi: 10.1111/j.1463-1326.2010.01304.x.
• 26. Bahar A, Kashi Z, Daneshpour E, Akha O, Ala S. Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial. Medicine (Baltimore). 2016;95(40):e4818. doi: 10.1097/MD.0000000000004818.
• 27. Pala NA, Laway BA, Misgar RA, Dar RA. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol Metab Syndr. 2015;7:99. Published 2015 Nov 14. doi: 10.1186/s13098-015-0094-4.
• 28. Berinder K, Nyström T, Höybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011;14(3):199-207. doi: 10.1007/s11102-010-0277-9.
• 29. Naliato EC, Violante AH, Gaccione M, et al. Body fat in men with prolactinoma. J Endocrinol Invest. 2008;31(11):985-990. doi: 10.1007/BF03345636.
• 30. Naliato EC, Violante AH, Caldas D, et al. Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol (Oxf). 2007;67(6):845-852. doi: 10.1111/j.1365-2265.2007.02973.x.
• 31. dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011;19(4):800-805. doi: 10.1038/oby.2010.150.
• 32. Korner J, Lo J, Freda PU, Wardlaw SL. Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia. Obes Res. 2003;11(2):311-312. doi: 10.1038/oby.2003.46.
• 33. Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf). 2013;79(6):845-852. doi: 10.1111/cen.12204.
• 34. Pelkonen R, Nikkilä EA, Grahne B. Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf). 1982;16(4):383-390. doi: 10.1111/j.1365-2265.1982.tb00731.x.
• 35. Medic-Stojanoska M, Icin T, Pletikosic I, et al. Risk factors for accelerated atherosclerosis in young women with hyperprolactinemia. Med Hypotheses. 2015;84(4):321-326. doi: 10.1016/j.mehy.2015.01.024.
• 36. Heshmati HM, Turpin G, de Gennes JL. Chronic hyperprolactinemia and plasma lipids in women. Klin Wochenschr. 1987;65(11):516-519. doi: 10.1007/BF01721038.
• 37. Schwetz V, Librizzi R, Trummer C, et al. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas. Metab Brain Dis. 2017;32(1):155-161. doi: 10.1007/s11011-016-9882-2.
• 38. Contreras F, Foullioux C, Pacheco B, et al. Effect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects. Am J Ther. 2008;15(4):397-402. doi: 10.1097/MJT.0b013e318160c353.
• 39. Posawetz AS, Trummer C, Pandis M, et al. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study. BMC Endocr Disord. 2021;21(1):81. doi: 10.1186/s12902-021-00733-6.
• 40. Auriemma RS, Galdiero M, Vitale P, et al. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology. 2015;101(1):66-81. doi: 10.1159/000371851.
• 41. Demir D, Demir AN, Sulu C, et al. The Combination of Dopamine Agonist Treatment and Surgery May Be the Best Option in Challenging Prolactinoma Cases: A Single-Centre Experience. World Neurosurg. 2023;175:e1166-e1174. doi: 10.1016/j.wneu.2023.04.089.
• 42. Zulfaliyeva G, Demir AN, Cetintas SC, Ozaydin D, Tanriover N, Kadioglu P. Role of Medical and Surgical Treatment in Management of the Patients With Prolactinoma: A Single-Center Experience. Exp Clin Endocrinol Diabetes. 2024 Oct;132(10):570-580. doi: 10.1055/a-2364-6027
• 43. Ozaydin D, Demir AN, Tanriover N. Evaluation of the gender effect in operated prolactinomas. Eur Res J. 2023;9(5):1135-1141. doi: 10.18621/eurj.1340508.